Fridkin S K, Edwards J R, Courval J M, Hill H, Tenover F C, Lawton R, Gaynes R P, McGowan J E
Division of Healthcare Quality Promotion, National Center for Infectious Diseases, Centers for Disease Control and Prevention, MS A-35, 1600 Clifton Road, Atlanta, GA 30333, USA.
Ann Intern Med. 2001 Aug 7;135(3):175-83. doi: 10.7326/0003-4819-135-3-200108070-00009.
Patient-specific risk factors for acquisition of vancomycin-resistant enterococci (VRE) among hospitalized patients are becoming well defined. However, few studies have reported data on the institutional risk factors, including rates of antimicrobial use, that predict rates of VRE. Identifying modifiable institutional factors can advance quality-improvement efforts to minimize hospital-acquired infections with VRE.
To determine the independent importance of any association between antimicrobial use and risk factors for nosocomial infection on rates of VRE in intensive care units (ICUs).
Prospective ecologic study.
126 adult ICUs from 60 U.S. hospitals from January 1996 through July 1999.
All patients admitted to participating ICUs.
Monthly use of antimicrobial agents (defined daily doses per 1000 patient-days), nosocomial infection rates, and susceptibilities of all tested enterococci isolated from clinical cultures.
Prevalence of VRE (median, 10%; range, 0% to 59%) varied by type of ICU and by teaching status and size of the hospital. Prevalence of VRE was strongly associated with VRE prevalence among inpatient non-ICU areas and outpatient areas in the hospital, ventilator-days per 1000 patient-days, and rate of parenteral vancomycin use. In a weighted linear regression model controlling for type of ICU and rates of VRE among non-ICU inpatient areas, rates of vancomycin use (P < 0.001) and third-generation cephalosporin use (P = 0.02) were independently associated with VRE prevalence.
Higher rates of vancomycin or third-generation cephalosporin use were associated with increased prevalence of VRE, independent of other ICU characteristics and the endemic VRE prevalence elsewhere in the hospital. Decreasing the use rates of these antimicrobial agents could reduce rates of VRE in ICUs.
住院患者获得耐万古霉素肠球菌(VRE)的个体特异性危险因素已逐渐明确。然而,鲜有研究报道包括抗菌药物使用率在内的机构危险因素对VRE发生率的预测数据。识别可改变的机构因素有助于推进质量改进工作,以尽量减少医院获得性VRE感染。
确定抗菌药物使用与医院感染危险因素之间的任何关联对重症监护病房(ICU)中VRE发生率的独立影响。
前瞻性生态学研究。
1996年1月至1999年7月期间,来自美国60家医院的126个成人ICU。
所有入住参与研究ICU的患者。
每月抗菌药物使用情况(每1000患者日的限定日剂量)、医院感染率以及从临床培养物中分离出的所有检测肠球菌的药敏情况。
VRE的患病率(中位数为10%;范围为0%至59%)因ICU类型、医院教学状况和规模而异。VRE的患病率与医院住院非ICU区域和门诊区域的VRE患病率、每1000患者日的呼吸机使用天数以及静脉用万古霉素的使用率密切相关。在一个控制了ICU类型和非ICU住院区域VRE发生率的加权线性回归模型中,万古霉素使用率(P < 0.001)和第三代头孢菌素使用率(P = 0.02)与VRE患病率独立相关。
万古霉素或第三代头孢菌素的较高使用率与VRE患病率增加相关,独立于其他ICU特征以及医院其他地方VRE的流行情况。降低这些抗菌药物的使用率可降低ICU中VRE的发生率。